Scarica l'app Stockscreener
11.09
2.34%
-0.23
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Sentiment analysis tools applied to ARS Pharmaceuticals Inc.2025 Top Decliners & Verified Stock Trade Ideas - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineWeekly Risk Report & Safe Entry Momentum Tips - newser.com
How to track smart money flows in ARS Pharmaceuticals Inc.Market Trend Summary & Accurate Trade Setup Notifications - newser.com
Epi Spray Maker Urges FDA to Require More Study of Epi Film - Allergic Living
Pattern recognition hints at ARS Pharmaceuticals Inc. upside2025 Price Momentum & Long-Term Safe Return Strategies - newser.com
Firm Helps Secure Favorable Decision from European Patent Office on Behalf of ARS Pharmaceuticals - Wilson Sonsini
ARS Pharmaceuticals' (SPRY) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
ARS Pharmaceuticals Hits Day High with 7.55% Surge to $11.11 - Markets Mojo
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy - MarketScreener
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, - openPR.com
Firm Advises ARS Pharma on Patent Matters Related to Loan Facility Up to $250 Million - Wilson Sonsini
ARS Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
ARS Pharma’s epinephrine nasal spray patent upheld in Europe By Investing.com - Investing.com Australia
ARS Pharma’s epinephrine nasal spray patent upheld in Europe - Investing.com
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) - The Manila Times
ARS Pharmaceuticals receives favorable decision from European Patent Office on patent related to neffy (epinephrine nasal spray) - MarketScreener
ARS Pharmaceuticals Receives Favorable Decision from - GlobeNewswire
EP 3678649 Upheld in 30+ Countries: ARS Pharmaceuticals' neffy® patent Secured Through 2039 - Stock Titan
Knights of Columbus Asset Advisors LLC Boosts Stock Position in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
What drives ARS Pharmaceuticals Inc stock priceEmerging Market Stocks & Your Free Entry to Smart Investing Starts Here - earlytimes.in
ARS Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Is ARS Pharmaceuticals Inc. building a consolidation baseWeekly Market Report & Safe Entry Point Identification - newser.com
Using data tools to time your ARS Pharmaceuticals Inc. exit2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
How to use Fibonacci retracement on ARS Pharmaceuticals Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
Published on: 2025-10-05 03:09:06 - newser.com
Is ARS Pharmaceuticals Inc. stock a buy before product launchesWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
A Look at ARS Pharmaceuticals’s Valuation Following Major $250M Funding for Neffy Commercial Growth - Sahm
ARS Pharmaceuticals (SPRY) Is Up 5.2% After Securing $250M Term Loan to Accelerate Neffy Launch – Has the Bull Case Changed? - Yahoo Finance
Why ARS Pharmaceuticals (SPRY) Is Up 7.8% After Securing $250M Loan and Japan Approval for neffy - Sahm
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - 富途牛牛
ARS Pharma secures $250M loan to accelerate Neffy rollout - MSN
William Blair Expects Lower Earnings for ARS Pharmaceuticals - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 6.6%Here's Why - MarketBeat
Epinephrine nasal spray maker ARS sues Aptar alleging device supply monopoly - Reuters
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity - citybiz
ARS Pharmaceuticals Locks In $250 Million To Grow Neffy - Finimize
RA Capital Management Funds Expansion of ARS Pharma Commercial Activity, Expands Portfolio of Financing Solutions for Innovative Healthcare Companies - WV News
ARS Pharmaceuticals Secures $250 Million Credit Agreement - MSN
ARS Pharma secures $100 million loan to accelerate neffy growth By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
ARS Pharma secures $100 million loan to accelerate neffy growth - Investing.com India
ARS Pharmaceuticals Secures Up to $250 Million Loan - GlobeNewswire
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy® - Yahoo Finance
ARS Pharmaceuticals, Inc. announced that it expects to receive $250 million in funding - MarketScreener
3.07%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):